GleamWall
中文EN

BSX BOSTON SCIENTIFIC CORP

Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 885725 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY25.1%
TTM EPS YoY26.7%
Revenue 3-yr CAGR15.3%
Net income 3-yr CAGR41.8%

Margins

Gross margin69.1%
Operating margin18.7%
Net margin16.6%
FCF margin15.8%
EBITDA margin25.5%

Returns

ROE14.3%
ROA7.9%
ROIC (approx.)10.6%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets43.1%
Debt / equity0.47x
Current ratio1.36x
Interest coverage10.46x

Cash quality & payout

Operating cash flow / net income1.21x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue4.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$5.14B$5.44B$5.20B$5.29B$5.07B$5.06B$4.66B$4.56B
Cost of revenue$1.71B$1.59B$1.59B$1.61B$1.52B$1.64B$1.45B$1.47B
Gross profit$3.43B$3.85B$3.61B$3.68B$3.54B$3.42B$3.21B$3.10B
R&D expense$520.00M$554.00M$516.00M$569.00M$514.00M$526.00M$443.00M$459.00M
SG&A expense$1.68B$1.80B$1.78B$1.83B$1.74B$1.72B$1.60B$1.61B
Operating income$828.00M$1.18B$1.10B$825.00M$1.05B$819.00M$921.00M$675.00M
Interest expense$100.00M$96.00M$90.00M$90.00M$87.00M$90.00M$82.00M$80.00M
Pretax income$733.00M$1.06B$1.16B$700.00M$939.00M$941.00M$805.00M$585.00M
Income tax$153.00M$155.00M-$176.00M$30.00M$183.00M$146.00M$133.00M$23.00M
Net income$582.00M$907.00M$1.34B$672.00M$755.00M$797.00M$674.00M$574.00M
EBITDA$1.19B$1.53B$1.45B$1.19B$1.17B$930.00M$1.25B$1.02B
EPS (basic)0.400.620.90—0.510.540.46—
EPS (diluted)0.400.610.90—0.510.530.45—
Weighted avg. shares (diluted)1.45B1.47B1.50B—1.50B1.49B1.49B—
Balance sheet
Cash & equivalents$609.00M$539.00M$1.45B$1.97B$1.27B$534.00M$725.00M$606.00M
Inventory$3.32B$3.23B$3.12B$2.94B$2.92B$2.86B$2.87B$2.81B
Current assets$8.16B$7.97B$8.68B$8.79B$8.04B$7.12B$7.33B$6.92B
PP&E, net$4.18B$4.13B$4.06B$4.04B$3.79B$3.46B$3.39B$3.29B
Goodwill$18.74B$18.64B$18.54B$18.28B$18.21B$18.08B$17.34B$17.09B
Intangibles$6.86B$6.92B$7.06B$7.02B$7.16B$7.26B$6.57B$6.68B
Total assets$45.46B$45.22B$44.35B$43.67B$42.71B$41.56B$40.14B$39.40B
Current liabilities$5.98B$6.43B$4.57B$5.44B$5.33B$5.19B$5.06B$6.40B
Short-term debt$1.04B$1.71B$41.00M$299.00M$483.00M$480.00M$777.00M$1.78B
Long-term debt$10.91B$10.91B$10.99B$11.14B$11.12B$11.11B$10.53B$8.97B
Total debt$11.95B$12.62B$11.03B$11.44B$11.60B$11.59B$11.31B$10.75B
Total liabilities$19.59B$20.04B$18.25B$19.20B$19.08B$18.91B$17.69B$17.39B
Shareholders' equity$25.63B$24.93B$25.86B$24.23B$23.39B$22.42B$22.21B$21.77B
Net debt$11.34B$12.09B$9.58B$9.47B$10.32B$11.05B$10.58B$10.14B
Cash flow statement
Operating cash flow$1.05B$1.47B$348.00M$1.36B$1.34B$1.29B$541.00M$1.46B
Capital expenditure$180.00M$195.00M$177.00M$351.00M$181.00M$157.00M$187.00M$277.00M
Free cash flow$868.00M$1.28B$171.00M$1.01B$1.16B$1.13B$354.00M$1.18B
Investing cash flow-$437.00M-$1.96B-$591.00M-$512.00M-$502.00M-$1.13B-$500.00M-$3.70B
Financing cash flow-$569.00M-$410.00M-$260.00M-$184.00M-$104.00M-$340.00M$233.00M$214.00M
Depreciation & amortization$361.00M$355.00M$351.00M$365.00M$117.00M$111.00M$325.00M$348.00M
Stock-based compensation$72.00M$87.00M$83.00M$71.00M$79.00M$75.00M$74.00M$69.00M
Dividends paid———————$0
Share buybacks$0———$0———

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.